BPI fold containing family B member 9, pseudogeneGenealiases: C20orf115 · dJ1187J4.2 · dJ1187J4.3
Q-omics provides the consensus-scored BPIFB9P profile across patient tissues and cancer cell-line models. BPIFB9P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BPIFB9P is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, BPIFB9P RNA expression shows 16,579 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where BPIFB9P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BPIFB9P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BPIFB9P survival associations across molecular data types. BPIFB9P RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BPIFB9P RNA expression–survival associations across cancer types. High BPIFB9P expression shows unfavorable associations in KIRC and LIHC, but favorable associations in HNSC, UCS, LAML and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for BPIFB9P RNA expression.
This table summarizes BPIFB9P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BPIFB9P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BPIFB9P shows lower tumor expression in LUSC and higher tumor expression in KICH, THCA, KIRC, COAD and KIRP. The KICH box plot shows higher BPIFB9P RNA expression in tumor versus normal tissue (log2 FC = +1.590, t-test p < 0.001).
This table shows molecular features associated with BPIFB9P in patient tissues and cancer cell lines. In patient samples, BPIFB9P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
